SILO
Silo Pharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Ample Liquidity
High Gross Profit Margin
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SILO
Silo Pharma, Inc.
A developmental stage biopharmaceutical company that developing products for indications such as PTSD and Alzheimer's disease
677 N. Washington Boulevard, Sarasota, Florida 34236
--
Silo Pharma, Inc., was incorporated in New York State on July 13, 2010. On January 24, 2013, the Company changed its domicile from New York to Delaware. On December 19, 2023, the company changed its state of incorporation from Delaware to Nevada. The company is a developing biopharmaceutical company focused on combining traditional therapies with psychedelic drug research to treat people with Alzheimer's, post-traumatic stress disorder and other rare neurological disorders.
Company Financials
EPS
SILO has released its 2025 Q2 earnings. EPS was reported at -0.19, versus the expected 0, missing expectations. The chart below visualizes how SILO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SILO has released its 2025 Q3 earnings report, with revenue of 18.02K, reflecting a YoY change of 0.00%, and net profit of -1.11M, showing a YoY change of -19.55%. The Sankey diagram below clearly presents SILO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
